Home › Ulcerative Colitis › Colorado › Colorado Springs
Ulcerative Colitis clinical trials in Colorado Springs, CO
14 studies for Ulcerative Colitis are looking for participants at sites in and around Colorado Springs (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RecruitingPhase 2
- Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 280507, Colorado Springs
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RecruitingPhase 4
- Peak Gastroenterology Associates, Colorado Springs
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 2
- Peak Gastroenterology Associates, Colorado Springs
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RecruitingPhase 2
- Site 033, Colorado Springs
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
RecruitingPhase 2
- Peak Gastroenterology Associates ( Site 1052), Colorado Springs
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RecruitingPhase 2
- Peak Gastroenterology Associates, Colorado Springs
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 3
- Peak Gastroenterology Associates, Colorado Springs
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
RecruitingPhase 2
- Peak Gastroenterology Associates, Colorado Springs
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 2
- Peak Gastroenterology Associates, Colorado Springs
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 3
- Peak Gastroenterology Associates - Colorado Springs - Site Number: 8400039, Colorado Springs
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 3
- Peak Gastroenterology Associates, Colorado Springs
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
RecruitingPhase 2
- Peak Gastroenterology Associates, Colorado Springs
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 3
- Peak Gastroenterology Associates - Colorado Springs - Site Number: 8400039, Colorado Springs
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RecruitingPhase 2
- Mirador Therapeutics Selected Site, Colorado Springs
About Ulcerative Colitis
Ulcerative Colitis (UC) can cause long-lasting swelling and ulcers in the large intestine. It is a type of inflammatory bowel disease. Find out more.
More about Ulcerative Colitis on MedlinePlus
Ulcerative Colitis trials in other cities
- New York City, NY23 studies
- Orlando, FL22 studies
- Miami, FL21 studies
- Houston, TX17 studies
- San Antonio, TX16 studies
- Tacoma, WA15 studies
- Chicago, IL15 studies
- San Diego, CA15 studies
- Tyler, TX14 studies
- Los Angeles, CA13 studies
- St. Louis, MO13 studies
- Washington, DC12 studies
Other studies in Colorado Springs
- Crohn's Disease13 studies
- Prostate Cancer12 studies
- Non-Small Cell Lung Cancer11 studies
- Lung Cancer8 studies
- Breast Cancer7 studies
- Asthma6 studies
- Colorectal Cancer6 studies
- Colon Cancer6 studies
- Head and Neck Squamous Cell Carcinoma4 studies
- Melanoma4 studies
- Rectal Cancer4 studies
- Inflammatory Bowel Disease4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.